Navigation Links
No difference in death rates among patients exposed to common rheumatoid arthritis drugs
Date:8/7/2012

New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). This population-based study of RA patients in Swedenthe first to compare mortality rates among patients treated with individual TNF inhibitorsis now available in Arthritis & Rheumatism, a journal published by Wiley on behalf of the American College of Rheumatology (ACR).

RA is a chronic, autoimmune disease characterized by inflammation in the joints that causes pain, tenderness and swelling. The World Health Organization estimates that RA affects up to one percent of individuals worldwide, with more than one million Americans diagnosed with the disease according to the ACR. Rheumatologists recommend early intervention with biologic disease modifying anti-rheumatic drugs (DMARDs) such as TNF inhibitors to slow disease progression, improve function, and prevent disability.

In Sweden nearly 15% of RA patients are prescribed TNF inhibitors. The present study examined the mortality rates in RA patients exposed to adalimumab, etanercept, or infliximab. "Understanding risk versus benefits of treatment with the most commonly prescribed biologics is important for physicians and patients in managing RA," said lead author Dr. Julia Fridman Simard with the Clinical Epidemiology Unit at Karolinska Institute in Stockholm, Sweden.

Researchers linked data from the Swedish Biologics Register (ARTIS), a comprehensive database of patients initiating first-ever biologic therapy for rheumatic diseases, and information from national Swedish registers that included data such as all-cause mortality, demographics, and RA characteristics. Between 2003 and 2008, 1,609 patients with RA initiated treatment with adalimumab, 2,686 with etanercept, and 2,027 with infliximab as their first ever biologic DMARD.

There were more than 19,000 person-years of follow-up during the five-year study period during which time 211 patients died (3.3%). "While we found no statistically significant difference in mortality rates across the three biologic therapies, further studies are needed to determine if this is true across certain subsets of patients with RA," concludes Dr. Simard.


'/>"/>
Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Related medicine news :

1. Study finds significant skull differences between closely linked groups
2. Mayo Clinic study links healthy muscle mass to healthy bones, finds differences by gender
3. Pre-season fitness makes no difference to risk of injury
4. Love Knows No Gender Difference
5. Racial differences in diabetes diagnostic thresholds
6. Higher-spending hospitals have fewer deaths for emergency patients
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Cancer Diagnosis May Raise Odds for Suicide, Heart Attack Death
9. Death From Accidental Injuries Among Kids Drops 30%: CDC
10. Opioids associated with highest risk of death
11. Study reveals major funding shortfall and high death rates for emergency laparotomy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... As the standards ... a communications platform that positions them as the go-to thought leader in all ... online publication as an always-on, always-fresh news, views and advocacy engine, called ONS ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She ... Record, The majority of cases litigated under ERISA involve claims for long-term disability ...
(Date:3/24/2017)... , ... March 24, 2017 , ... Viewers who like ... of critical historical facts, cultural practices, goods, services, and societal issues tend to appreciate ... look into the popular practice of utilizing running events for causes around the world. ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... year of enhancements, upgrading their training and leads programs. , In February, 2017, ... for elite sales agents, Performance Partners is designed to teach how to maximize ...
(Date:3/24/2017)... ... 2017 , ... “Finding Christ Through Social Media: Year One ... the writer’s path toward true communion with God. “Finding Christ Through Social Media: ... creation of published author Lea Michelle Johnson, a follower of Christ, wife and ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 24, 2017 A ReportsnReports.com report ... been growing rapidly as the global sales of Adcetris and Kadcyla ... in the antibody drug conjugates market is driven by large number ... and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 ...
(Date:3/24/2017)... DIEGO , March 24, 2017  GenomeDx Biosciences ... Resource Information Database) and Decipher® Prostate Cancer Classifier tests ... European Association of Urology (EAU) Congress held March 24 ... . The Annual EAU Congress is Europe,s ... most comprehensive research in the urological field. ...
(Date:3/24/2017)...  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com ... and dermatology biopharmaceutical company, today disclosed terms of ... (the "Definitive Financing") it entered into on March ... who are referred to in the Definitive Financing ... with the Securities and Exchange Commission.   ...
Breaking Medicine Technology: